A human recombinant haemoglobin designed for use as a blood substitute

Area of Science:

• Biochemistry
• Biotechnology
• Hematology

Background:

• Urgent need for blood substitutes due to concerns over blood-transmitted pathogens.
• Existing cell-free hemoglobin solutions face challenges with oxygen unloading and renal toxicity.
• Hemoglobin synthesized in E. coli and S. cerevisiae also exhibit limitations.

Purpose of the Study:

• To engineer a novel human hemoglobin with improved oxygen-carrying capacity and reduced toxicity for use as a blood substitute.
• To address the high oxygen affinity and rapid renal clearance issues of previous hemoglobin-based oxygen carriers.
• To develop a stable hemoglobin molecule that prevents dissociation into toxic dimers.

Main Methods:

• Utilized an expression vector for producing human hemoglobin.
• Incorporated a gene encoding a mutant beta-globin with decreased oxygen affinity.
• Included a duplicated, tandemly fused alpha-globin gene to enhance stability.
• Investigated the in vivo half-life and renal clearance of the engineered hemoglobin.

Main Results:

• Successfully produced a human hemoglobin with decreased oxygen affinity.
• The fused alpha-globin subunits prevented dissociation into alpha beta dimers.
• The engineered hemoglobin demonstrated increased half-life in vivo.
• Elimination of renal toxicity associated with hemoglobin dissociation was observed.

Conclusions:

• The engineered human hemoglobin effectively addresses the limitations of previous blood substitute candidates.
• This novel hemoglobin exhibits reduced oxygen affinity and enhanced stability, making it a promising blood substitute.
• The prevention of dimer dissociation mitigates renal toxicity, offering a safer alternative for oxygen delivery.